Food and Drug Administration (FDA) has approved the first drug shown to substantially extend the lives of people with advanced pancreatic cancer, nearly doubling survival time in a key clinical trial.
Food and Drug Administration (FDA) has approved the first drug shown to substantially extend the lives of people with advanced pancreatic cancer, nearly doubling survival time in a key clinical trial.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Food and Drug Administration (FDA) has approved the first drug shown to substantially extend the lives of people with advanced pancreatic cancer, nearly doubling survival time in a key clinical trial.
Open the app view to save this story, compare related coverage, and continue from the same source.